Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies

被引:6
作者
Rudofsky, Gottfried [1 ]
Amadid, Hanan [2 ]
Braae, Uffe Christian [2 ]
Catrina, Sergiu-Bogdan [3 ,4 ]
Kick, Anastas [5 ]
Mandavya, Kabirdev [6 ]
Roslind, Klaus [7 ]
Saravanan, Ponnusamy [8 ,9 ,10 ]
van Houtum, William [11 ]
Jain, Akshay B. [11 ]
机构
[1] Private Practice Endocrinol Diabet & Obes, Olten, Switzerland
[2] Novo Nordisk AS, Soborg, Denmark
[3] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[4] Acad Specialist Ctr, Ctr Diabet, Stockholm, Sweden
[5] Primary Care Grp Practice Sanacare, Lugano, Switzerland
[6] Novo Nordisk Serv Ctr India Pvt Ltd, Bangalore, India
[7] Aarup Hlth Ctr IS, Aarup, Denmark
[8] Univ Warwick, Warwick Med Sch, Coventry, England
[9] Univ Warwick, Ctr Global Hlth, Warwick Acad Hlth, Coventry, England
[10] George Eliot Hosp, Dept Diabet Endocrinol & Metab, Nuneaton, England
[11] Spaarne Ziekenhuis Hoofddorp, Dept Internal Med, Hoofddorp, Netherlands
关键词
Body weight; GLP-1 receptor agonist; Glucose-lowering medication; Glycemic control; HbA(1C); Incretin therapy; Real-world evidence; Semaglutide; Type; 2; diabetes; ONCE-WEEKLY DULAGLUTIDE; WEIGHT CHANGE; LIRAGLUTIDE; EFFICACY; GREATER-THAN-OR-EQUAL-TO-65;
D O I
10.1007/s13300-024-01668-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Oral semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA) approved for improving glycemic control in adults with type 2 diabetes (T2D). The PIONEER REAL program evaluates clinical and patient-reported outcomes of oral semaglutide treatment as part of routine clinical practice across 13 countries. Here, data from Canada, Denmark, Italy, the Netherlands, Sweden, Switzerland, and the UK are pooled and analyzed to address treatment satisfaction as well as glycated hemoglobin (HbA(1C)) and body weight changes in relevant subgroup analyses. Methods: This pooled analysis encompasses seven country-specific, non-interventional, multicenter, phase 4, prospective, single-arm clinical studies assessing the use of oral semaglutide in adults with T2D. Primary endpoint was the change in HbA(1C) from baseline to end of study (EOS), and secondary endpoints included changes in body weight and treatment satisfaction. For the analyses, results were stratified by age, T2D duration, and oral semaglutide dose at EOS as well as baseline HbA(1C), body weight, and body mass index. Results: Oral semaglutide treatment was initiated by 1615 participants. At EOS, 1222 (76%) participants out of the 1483 (92%) who completed the study were on treatment. Estimated changes in HbA(1C) and body weight from baseline to week 38 were - 1.0%-point (95% CI - 1.08 to - 0.97; P < 0.0001) and - 5.0% (CI - 5.37 to - 4.72; P < 0.0001). Treatment satisfaction increased significantly during the study. Shorter T2D duration interacted with higher HbA(1C) reduction and body weight loss. Interaction was also observed between higher baseline HbA(1C) and more pronounced decrease in HbA(1C). No significant interactions were detected between clinical outcomes and age or physician setting. Conclusion: The PIONEER REAL pooled analysis shows that people initiating oral semaglutide treatment experience improved glycemic control and body weight loss across age groups and T2D duration. This occurs regardless of specialist or primary care practice setting and is accompanied by an increased treatment satisfaction. Clinical Trial Registrations: NCT04559815 (Canada), NCT04537637 (Denmark), NCT05230615 (Italy), NCT04601740 (the Netherlands), NCT04601753 (Sweden), NCT04537624 (Switzerland), NCT04862923 (UK).
引用
收藏
页码:73 / 87
页数:15
相关论文
共 39 条
[1]  
[Anonymous], 2009, Ethical Principles for Medical Research Involving Human Subjects, DOI DOI 10.1515/9783110208856.233
[2]   Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme [J].
Aroda, Vanita R. ;
Bauer, Robert ;
Christiansen, Erik ;
Haluzik, Martin ;
Kallenbach, Klaus ;
Montanya, Eduard ;
Rosenstock, Julio ;
Meier, Juris J. .
DIABETES OBESITY & METABOLISM, 2022, 24 (07) :1338-1350
[3]   Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study [J].
Aroda, Vanita R. ;
Faurby, Mads ;
Lophaven, Soren ;
Noone, Josh ;
Wolden, Michael Lyng ;
Lingvay, Ildiko .
DIABETES OBESITY & METABOLISM, 2021, 23 (09) :2177-2182
[4]   PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes [J].
Aroda, Vanita R. ;
Rosenstock, Julio ;
Terauchi, Yasuo ;
Altuntas, Yuksel ;
Lalic, Nebojsa M. ;
Morales Villegas, Enrique C. ;
Jeppesen, Ole K. ;
Christiansen, Erik ;
Hertz, Christin L. ;
Haluzik, Martin .
DIABETES CARE, 2019, 42 (09) :1724-1732
[5]   Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes [J].
Blonde, Lawrence ;
Pencek, Richard ;
MacConell, Leigh .
CARDIOVASCULAR DIABETOLOGY, 2015, 14
[6]   Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ≥65 and <65 Years of Age: A Pooled Analysis from Phase III Studies [J].
Bode, Bruce W. ;
Brett, Jason ;
Falahati, Ali ;
Pratley, Richard E. .
AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2011, 9 (06) :423-433
[7]   Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and &lt;65 years [J].
Boustani, M. A. ;
Pittman, I. ;
Yu, M. ;
Thieu, V. T. ;
Varnado, O. J. ;
Juneja, R. .
DIABETES OBESITY & METABOLISM, 2016, 18 (08) :820-828
[8]  
Bradley C., 1994, Handbook of Psychology and Diabetes, P111, DOI DOI 10.4324/9781315077369
[9]   The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ [J].
Bradley, Clare ;
Plowright, Rosalind ;
Stewart, John ;
Valentine, John ;
Witthaus, Elke .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2007, 5 (1)
[10]   PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice [J].
Catrina, Sergiu-Bogdan ;
Amadid, Hanan ;
Braae, Uffe C. ;
Dereke, Jonatan ;
Ekberg, Neda Rajamand ;
Klanger, Boris ;
Jansson, Stefan .
DIABETES THERAPY, 2024, 15 (09) :2079-2095